Irbesartan Recruiting Phase 3 Trials for Ehlers-Danlos Syndrome, Vascular Type Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02597361Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)